AFFINIVAX
Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases. This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existing vaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today. The company is rapidly advancing... a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform.
AFFINIVAX
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2014-06-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.affinivax.com
Total Employee:
51+
Status:
Active
Contact:
617-465-0865
Total Funding:
377.49 M USD
Technology used in webpage:
Person Schema Google Google Cloud Gravatar Profiles
Similar Organizations
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Canopy Growth
Canopy Growth is a cannabis consumer product company that manufactures medical cannabis to improve lives.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Centessa Pharmaceuticals
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process.
Visby Medical
Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases.
Esperion
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.
Insmed
We are a publicly traded (NASDAQ: INSM) biopharmaceutical company dedicated to improving the lives of patients battling serious lung
Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Bausch Health
Bausch Health is a develops and markets medications used in the fields of neurology, dermatology and infectious diseases.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
2020-04-23
Board_member
2020-04-23
Board_member
2014-05-01
Current Employees Featured
Steven Brugger President and CEO @ Affinivax
President and CEO
2013-01-01
Kamran Tavangar Chief Operating Officer @ Affinivax
Chief Operating Officer
Stuart Chaffee CBO @ Affinivax
CBO
Shite Sebastian Vice President & Head of Product Development @ Affinivax
Vice President & Head of Product Development
Richard Malley Scientific Founder & Board Member @ Affinivax
Scientific Founder & Board Member
2014-06-01
Frank J. Malinoski SVP of Clinical Development and Regulatory Affairs @ Affinivax
SVP of Clinical Development and Regulatory Affairs
George Siber Co-Founder & Member of BOD @ Affinivax
Co-Founder & Member of BOD
2014-06-01
Gilles Besin Executive Director & Head of Discovery Research @ Affinivax
Executive Director & Head of Discovery Research
David Slatcher VP of Corporate Controller @ Affinivax
VP of Corporate Controller
Nathan McBride Vice President, IT @ Affinivax
Vice President, IT
2021-06-01
Founder
Investors List
CARB-X
CARB-X investment in Grant - Affinivax
EcoR1 Capital
EcoR1 Capital investment in Series C - Affinivax
Rock Springs Capital
Rock Springs Capital investment in Series C - Affinivax
Ziff Capital Partners
Ziff Capital Partners investment in Series C - Affinivax
Surveyor Capital
Surveyor Capital investment in Series C - Affinivax
T. Rowe Price
T. Rowe Price investment in Series C - Affinivax
Logos Capital
Logos Capital investment in Series C - Affinivax
Foresite Capital
Foresite Capital investment in Series C - Affinivax
Wellington Management
Wellington Management investment in Series C - Affinivax
Viking Global Investors
Viking Global Investors investment in Series C - Affinivax
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-16 | Affinivax Appoints Vanya Sagar as Chief People Officer |
| 2021-08-09 | Affinivax Appoints Kara Bickham, MD, as Chief Medical Officer |
Official Site Inspections
http://www.affinivax.com
- Host name: 144.236.160.34.bc.googleusercontent.com
- IP address: 34.160.236.144
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Affinivax"
GSK completes acquisition of Affinivax, Inc.
Aug 16, 2022 GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge …See details»
Affinivax Inc. - LinkedIn
Affinivax Inc. | 11,041 followers on LinkedIn. Affinivax was acquired by GSK in August 2022. Affinivax is a clinical stage biotechnology company developing a next generation approach in …See details»
GSK completes acquisition of Affinivax, Inc. | GSK US
Aug 16, 2022 GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge …See details»
GSK to acquire clinical-stage biopharmaceutical company …
Affinivax, Inc. Company Profile | Cambridge, MA | Competitors ...
Find company research, competitor information, contact details & financial data for Affinivax, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
GSK completes acquisition of Affinivax, Inc.
Issued: 16 August 2022, London UK GSK completes acquisition of Affinivax, Inc. GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc …See details»
GSK will buy vaccine developer Affinivax - Chemical & Engineering …
Jun 3, 2022 GSK has agreed to buy the vaccine developer Affinivax for $2.1 billion, plus up to $1.2 billion in milestone payments. Affinivax, based in Cambridge, Massachusetts, uses its …See details»
GSK to buy US biotech group Affinivax in $3bn deal - Financial Times
May 31, 2022 GlaxoSmithKline is buying Boston-based biotech Affinivax in a transaction worth up to $3.3bn, bolstering its vaccines business with new technology.See details»
GSK completes acquisition of Affinivax, Inc. - PharmiWeb.com
Aug 16, 2022 GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge …See details»
GSK to buy biopharmaceutical company Affinivax
May 31, 2022 GLAXOSMITHKLINE (GSK) has announced it will buy biopharmaceutical company Affinivax, in a deal worth approximately US$3.3bn. Affinivax, which is based in …See details»
GSK will buy vaccine firm Affinivax | C&EN Global Enterprise
Jun 6, 2022 GSK has agreed to buy the vaccine developer Affinivax for $2.1 billion, plus up to $1.2 billion in milestone payments. Affinivax, based in Cambridge, Massachusetts, uses its …See details»
GSK to Boost Vaccine Portfolio With Affinivax Acquisition
May 31, 2022 GSK plc GSK announced that it has entered into a definitive agreement with Massachusetts-based privately held biopharmaceutical company, Affinivax, Inc., wherein it will …See details»
GSK to acquire Affinivax, Inc. - Sharecast.com
Issued: 31 May 2022, London UK - LSE announcement GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc. · GSK to pay $2.1 billion upfront and up to $1.2 …See details»
Affinivax Inc - Company Profile and News - Bloomberg Markets
Company profile page for Affinivax Inc including stock price, company news, executives, board members, and contact informationSee details»
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine ...
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline Nat Rev Drug Discov. 2022 Jul;21(7):480-481. doi: 10.1038/d41573-022-00103-4.See details»
Working At Affinivax: Company Overview and Culture - Zippia
Mar 14, 2024 Organization Type. Private. CEO. Steven B Brugger. Social Media. Affinivax is a biotechnology company developing a novel conjugation technology with the goal of designing …See details»
Affinivax - Bill & Melinda Gates Foundation
Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing multiple antigens to be incorporated in …See details»
Affinivax CEO And Leadership: Executives and Demographics
Nov 18, 2022 Here are further demographic highlights of the leadership team: The Affinivax executive team is 32% female and 68% male.; 66% of the management team is White.; 6% of …See details»
Affinivax Careers and Employment | Indeed.com
Apr 2, 2019 Find out what works well at Affinivax from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles …See details»
Apotex acquires US rights to PROVIGIL® (modafinil) and
2 days ago Organization Profile. Apotex Inc. Also from this source. Apotex, through its specialty pharma division, Searchlight, expands branded dermatology portfolio through the in-licensing …See details»